Source comparison
CJC-1295 No DAC vs Ipamorelin: Efficacy Data and Stacking Rationale
Research protocols evaluating CJC-1295 no DAC as a solo agent typically report sustained GH elevation lasting 90–180 minutes, with peak plasma levels occurring 30–60 minutes post-injection. The magnitude of GH increase depends heavily on baseline endogenous GH
This comparison does not assign a generated winner or score.
- Research protocols evaluating CJC-1295 no DAC as a solo agent typically report sustained GH elevation lasting 90–180 minutes, with peak plasma levels occurring 30–60 minutes post-injection. The magnitude of GH increase depends heavily on baseline endogenous GH status, time of day, and fasting state. Ipamorelin administered alone produces sharper, shorter-duration GH spikes, with studies showing 2–3× baseline GH at peak and return to baseline within 120 minutes.
- The stacking advantage is quantifiable. Research comparing CJC-1295 no DAC + Ipamorelin co-administration to either peptide alone demonstrates GH output 3–5× higher than solo GHRH analog use and 2–3× higher than solo Ipamorelin. This synergy occurs because GHRH pathway activation primes somatotroph cells while ghrelin receptor stimulation provides the trigger signal. Dual activation bypasses somatostatin's suppressive effect more effectively. Standard research dosing for stacked protocols: 100–200 mcg CJC-1295 no DAC + 200–300 mcg Ipamorelin, administered 2–3 times daily.
- Investigators using CJC-1295 no DAC or Ipamorelin in isolation often report inconsistent GH response or plateauing effects after 4–6 weeks. Likely due to receptor downregulation or compensatory somatostatin upregulation. Stacked protocols show more sustained response over 8–12 week timelines.
- For researchers sourcing peptides, quality verification is non-negotiable. CJC1295 Ipamorelin 5MG 5MG provides pre-blended, lyophilized formulations synthesized under controlled conditions with third-party purity validation.